ClinicalTrials.gg
CompletedNCT07405268Updated Nov 17, 2026

Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's Disease

An observational study in Parkinson Disease (PD), Periodontitis and Periodontal Diseases, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Saglik Bilimleri Universitesi · Observational

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
136
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.

Enrollment
6th of 73
136 · median 61
Started
2026
with 28 others
Observational
73 of 172
23 open now
Registered
138th of 172
by date
Lead sponsor
5 of 172
Saglik Bilimleri Universitesi

Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 6th largest by enrollment of the 73 observational ones that give a count, is one of 29 that started in 2026, is one of 73 observational ones, and was the 138th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Parkinson Disease with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effects of Levodopa-Benserazide drug combination on periodontal status and salivary cytokine levels in patients with Parkinson's disease. The study includes four groups: Parkinson's patients with periodontitis, periodontally healthy Parkinson's patients, participants without Parkinson's with periodontitis, and periodontally healthy participants without Parkinson's. Clinical periodontal parameters (Plaque Index, Gingival Index, Bleeding on Probing, Pocket Depth, and Clinical Attachment Loss) will be recorded. Unstimulated saliva samples will be collected to analyze the levels of TNF-alpha, RANTES, IL-10, IL-13, Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Malondialdehyde (MDA).

Read the detailed description

Background and Rationale: Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra. Chronic inflammation and oxidative stress are considered significant factors in the progression of PD. Levodopa (L-DOPA), combined with Benserazide, remains the most effective pharmacological treatment for managing PD symptoms. Periodontitis is a chronic inflammatory disease that leads to the destruction of tooth-supporting tissues and is associated with elevated levels of local and systemic inflammatory cytokines such as TNF-alpha, IL-10, IL-13, and RANTES. Recent studies suggest a bidirectional relationship between systemic inflammation and neurodegenerative diseases. This study aims to evaluate the effects of the Levodopa-Benserazide drug combination on periodontal status and salivary inflammatory cytokine levels in patients with Parkinson's Disease.

Study Design and Setting: This cross-sectional, case-control study will be conducted in collaboration with the Department of Periodontology at the University of Health Sciences, Gulhane Faculty of Dentistry, and the Department of Neurology at Hacettepe University Faculty of Medicine.

Participants and Groups: The study will include a total of 136 participants divided into four groups (n=34 per group):

Parkinson's patients with periodontitis

Periodontally healthy Parkinson's patients

Systemically healthy participants with periodontitis (Control)

Systemically and periodontally healthy participants (Control)

Diagnosis of Parkinson's Disease will be confirmed based on the United Kingdom Parkinson's Disease Society Brain Bank Criteria.

Exclusion Criteria: Participants will be excluded if they have active smoking habits, diabetes mellitus, history of antibiotic or anti-inflammatory drug use in the last 3 months, periodontal treatment in the last month, use of probiotics or oral antiseptics in the last month, history of radiotherapy/chemotherapy in the last 6 months, presence of fewer than 16 natural teeth, use of removable partial or complete dentures, or inability to give informed consent due to dementia or other cognitive impairments.

Clinical Evaluations: All participants will undergo a comprehensive periodontal examination. Clinical parameters including Plaque Index (PI) (Silness-Löe), Gingival Index (GI) (Löe-Silness), Bleeding on Probing (BOP), Pocket Depth (PD), and Clinical Attachment Loss (CAL) will be recorded using a Williams periodontal probe. Measurements for PD, CAL, and BOP will be taken at six sites per tooth, while PI and GI will be recorded at four sites per tooth.

Biochemical Analysis: Unstimulated whole saliva samples will be collected from all participants between 09:00 and 10:00 AM to minimize circadian rhythm variations. Participants will be asked to refrain from eating, drinking, or oral hygiene procedures for at least one hour prior to collection. Samples will be stored at -80°C until analysis.

Inflammatory cytokines (TNF-alpha, RANTES, IL-10, IL-13) will be analyzed using Enzyme-Linked Immunosorbent Assay (ELISA).

Oxidative stress markers, including Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Malondialdehyde (MDA), will be measured using spectrophotometric methods.

Statistical Analysis: Data distribution will be assessed using the Kolmogorov-Smirnov test. Differences between groups will be analyzed using ANOVA (for normally distributed data) or appropriate non-parametric tests. Categorical variables will be compared using the Chi-square test. A p-value of \<0.05 will be considered statistically significant.

03

Conditions studied

  • Parkinson Disease (PD)
  • Periodontitis
  • Periodontal Diseases

Keywords

  • Levodopa
  • Benserazide
  • Salivary Cytokines
  • Oxidative Stress
  • Inflammation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from the Department of Neurology at Hacettepe University Faculty of Medicine (Parkinson's patients) and the Department of Periodontology at the University of Health Sciences, Gulhane Faculty of Dentistry (Periodontitis patients and healthy controls).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Parkinson's Disease according to United Kingdom Parkinson's Disease Society Brain Bank Criteria (for study group).
  • Systemically healthy individuals (for control group).
  • Willingness to participate and sign .

Exclusion criteria

Exclusion Criteria:

  • Active smoking.
  • Comprehensive periodontal treatment within the last month.
  • Oral, respiratory, or digestive system diseases within the last 3 months.
  • Fewer than 16 natural teeth.
  • Use of full or removable partial dentures.
  • Dementia or inability to provide consent.
  • Serious active illnesses or substance abuse.
  • Antibiotic treatment within the last 3 months.
  • Probiotic use within the last month.
  • Radiotherapy/chemotherapy within the last 6 months.
  • Use of oral antiseptics within the last month.
  • Diabetes mellitus.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
136 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Parkinson's - Periodontitis

    Patients diagnosed with Parkinson's Disease who also have Periodontitis.

  • Parkinson's - Healthy

    Patients diagnosed with Parkinson's Disease who are periodontally healthy.

  • Control - Periodontitis

    Systemically healthy participants (non-Parkinson) who have Periodontitis.

  • Control - Healthy

    Systemically and periodontally healthy participants.

06

What researchers measure

Primary outcomes

  1. Salivary Inflammatory Cytokine

    TNF-alpha,

    Time frame: Day 1

  2. Salivary Inflammatory Cytokine

    RANTES

    Time frame: Day 1

  3. Salivary Inflammatory Cytokine

    IL-10

    Time frame: Day 1

  4. Salivary Inflammatory Cytokine

    IL-13

    Time frame: Day 1

  5. Salivary Oxidative Stress Levels

    Total Oxidant Status (TOS)

    Time frame: Day 1

  6. Salivary Oxidative Stress Levels

    Total Antioxidant Status (TAS)

    Time frame: Day 1

  7. Salivary Oxidative Stress Levels

    Malondialdehyde (MDA)

    Time frame: Day 1

Secondary outcomes

  1. Clinical Periodontal Parameters

    Assessment of Plaque Index (PI)

    Time frame: Day 1

  2. Clinical Periodontal Parameters

    Bleeding on Probing (BOP)

    Time frame: Day 1

  3. Clinical Periodontal Parameters

    Gingival Index (GI)

    Time frame: Day 1

  4. Clinical Periodontal Parameters

    Pocket Depth (PD)

    Time frame: Day 1

  5. Clinical Periodontal Parameters

    Clinical Attachment Loss (CAL)

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Publications

  • Wei X, Gibiansky L, Wang Y, Fuh F, Erickson R, O'Byrne S, Tang MT. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating beta7 Receptor Occupancy in Patients With Ulcerative Colitis. J Clin Pharmacol. 2018 Mar;58(3):386-398. doi: 10.1002/jcph.1031. Epub 2017 Nov 26. PubMed 29178491 ↗
  • Kononen E, Gursoy M, Gursoy UK. Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues. J Clin Med. 2019 Jul 31;8(8):1135. doi: 10.3390/jcm8081135. PubMed 31370168 ↗
  • Ye X, Chen J, Eric Irrgang M, Engel M, Dong A, Glotzer SC, Murray CB. Quasicrystalline nanocrystal superlattice with partial matching rules. Nat Mater. 2017 Feb;16(2):214-219. doi: 10.1038/nmat4759. Epub 2016 Sep 26. PubMed 27669053 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Oct 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 12, 2026
StartActual
Feb 10, 2026
Primary completionActual
Oct 13, 2026
CompletionActual
Nov 13, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 17, 2026
Sites
1 site added, 1 site removed
Show site
  • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi · Ankara, Turkey (Türkiye)
Show 1 removed
  • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi · Ankara, Turkey (Türkiye)
Nov 17, 2026
Primary completion
Oct 10, 2026→Oct 13, 2026 (actual)
Nov 17, 2026
Study completion
Nov 10, 2026→Nov 13, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi · Ankara, Turkey (Türkiye)
    Primary completion Oct 10, 2026→Oct 13, 2026 (now actual)
    Study completion Nov 10, 2026→Nov 13, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07405268
Responsible party
Özlem SARAÇ ATAGÜN (Assoc Prof Dr., Saglik Bilimleri Universitesi) — Principal investigator
First posted
Feb 12, 2026
Start date
Feb 10, 2026
Primary completion
Oct 13, 2026
Completion
Nov 13, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion